secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2026-03-12T23:59:59+00:00
Accession:  0001628280-26-017244
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Q4/FY25 net loss $274.4M; Phase 3 PiNACLE-H2H begins; cash $247.2M
------------------------------------------------------------------------

- FY25 net loss $274.4M vs $343.0M in FY24; Q4 net loss $140.7M (incl. $66.3M IPR&D for LYL273).
- Ronde-cel Phase 3 PiNACLE-H2H (2L LBCL) started dosing; Phase 1/2 PiNACLE 3L+ data shown at ASH 2025.
- LYL273 (GCC-targeted CAR-T) Phase 1 dosed 7 more mCRC patients; no DLT; dose escalated to Level 3.
- Smital Shah appointed CFO and Business Officer in March 2026; $50M equity tranche closed on milestone.
- Cash $247.2M at year-end 2025 (excl. $50M tranche); runway into Q2 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828026017244/0001628280-26-017244-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828026017244/lyel-20260312.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-017244

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer